Rentschler Biopharma Executive Board Changes: Interim CEO Uwe Buecheler Takes Helm As Leadership Transitions Continue

Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, has announced changes to its Executive Board as part of the next phase of its corporate strategy, focused on driving long-term growth and sustainable value creation.

Benedikt von Braunmuehl, Chief Executive Officer, and the Supervisory Board have mutually agreed that he will step down from his role on the Executive Board. To ensure continuity during this transition, Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, has been appointed as interim CEO, effective immediately, and will serve in this role until a new CEO is named.

Nikolaus F. Rentschler, PhD, Chairman of the Supervisory Board, expressed gratitude for von Braunmuehl’s contributions, stating that he laid important foundations and strengthened Rentschler Biopharma’s position in the market. “With the successful completion of this phase, the time has come to pass the implementation of our corporate strategy to new leadership. We sincerely thank Mr. von Braunmuehl for his significant contributions and wish him all the best in his future endeavors,” said Rentschler. Benedikt von Braunmuehl added, “I want to thank my colleagues for their dedication and collaboration across all sites. Rentschler Biopharma is well positioned for the future, and I wish the team continued success.”

In addition, Christiane Bardroff, Chief Operating Officer, has decided to pursue a new professional opportunity after four years with the company. She will leave Rentschler Biopharma during the first quarter of this year. Her successor has already been appointed by the Supervisory Board and will be announced soon. Nikolaus F. Rentschler highlighted Bardroff’s accomplishments, including the establishment of a new production line at the Milford, MA site, increased production efficiency at the Laupheim facility, and planning of the new buffer media station. “Her focus on operational excellence, quality, digitalization, and automation has provided important momentum for our continued growth,” he said.

Commenting on the leadership transition, Rentschler said, “Uwe Buecheler brings extensive international experience and has been closely involved in shaping our strategy. He is well positioned to guide Rentschler Biopharma during this next phase, ensuring sustainable value creation for our clients, patients, and markets.”

Uwe Buecheler, PhD, interim CEO, stated, “Rentschler Biopharma is in a strong operational and economic position. With the scale-up of our production capacity, our advanced development capabilities, and efficiency improvements across sites, we are entering a new phase focused on client satisfaction, proximity to clients, and business growth. My focus will be on working closely with our CFO, Gunnar Voss von Dahlen, the incoming COO, and our teams at Laupheim and Milford to effectively implement our corporate strategy. We remain committed to being a reliable partner in bioprocess development and manufacturing, guided by our vision of advancing medicine to save lives.”

Dr. Buecheler brings more than 30 years of experience in the global biopharmaceutical industry and the CDMO sector. Since 2024, he has served as Vice Chairman of Rentschler Biopharma’s Supervisory Board, contributing expertise in leadership, operations, and technology development. He has also played a key role in numerous global regulatory approvals and expansion projects, providing him with a broad international perspective and strategic insight